Natco Pharma hikes investment in US-based eGenesis to $16.7 million
· BS Companies
Natco Pharma Ltd on Monday said it has decided to increase its proposed investment in US-based biotechnology firm eGenesis Inc to USD 16.70 million (around Rs 139 crore) from the previously disclosed amount of USD 14 million.
Key facts
- Dates in focus
- October 31
Market context
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Stock Market Crash LIVE: Sensex Tanks Over 1,200 Points, Nifty 50 Below 22,200; ITC, JSW Steel, IndiGo Among Top Losers
INR vs USD: Rupee near 97/dollar; how TCS, Sun Pharma, Tata Steel, SRF may gain from weaker currency? Experts explain
Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price
Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October
Valiant Organics among 5 commodity stocks that hit 52-week highs and rallied up to 48% in a month